• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Canakinumab and Lung Cancer: Intriguing, but Is It Real?卡那单抗与肺癌：耐人寻味，但确有其事？
Oncologist. 2018 Jun;23(6):637-638. doi: 10.1634/theoncologist.2018-0116. Epub 2018 Apr 17.
2
Inhibition of Interleukin-1β by Canakinumab and Cardiovascular Outcomes in Patients With Chronic Kidney Disease.卡那奴单抗抑制白细胞介素-1β与慢性肾脏病患者的心血管结局。
J Am Coll Cardiol. 2018 May 29;71(21):2405-2414. doi: 10.1016/j.jacc.2018.03.490.
3
Pharmacokinetic and pharmacodynamic properties of canakinumab in patients with gouty arthritis.卡那单抗治疗痛风性关节炎患者的药代动力学和药效学特征。
J Clin Pharmacol. 2013 Dec;53(12):1240-51. doi: 10.1002/jcph.162. Epub 2013 Sep 30.
4
Effect of anti-IL-1β antibody (canakinumab) on insulin secretion rates in impaired glucose tolerance or type 2 diabetes: results of a randomized, placebo-controlled trial.抗白细胞介素-1β抗体（卡那单抗）对糖耐量受损或2型糖尿病患者胰岛素分泌率的影响：一项随机、安慰剂对照试验的结果
Diabetes Obes Metab. 2012 Dec;14(12):1088-96. doi: 10.1111/j.1463-1326.2012.01637.x. Epub 2012 Jul 19.
5
Multiple testing in the 'Canakinumab in atherosclerosis' trial: correction required?“卡那单抗治疗动脉粥样硬化”试验中的多重检验：是否需要校正？
Clin Exp Rheumatol. 2017 May-Jun;35 Suppl 104(2):24. Epub 2017 Apr 27.
6
Canakinumab for Atherosclerotic Disease.卡那单抗用于治疗动脉粥样硬化疾病。
N Engl J Med. 2018 Jan 11;378(2):199-200. doi: 10.1056/NEJMc1714635.
7
Pharmacokinetics and Pharmacodynamics of Canakinumab in Patients With Systemic Juvenile Idiopathic Arthritis.卡那单抗在全身型幼年特发性关节炎患者中的药代动力学和药效学
J Clin Pharmacol. 2016 Dec;56(12):1516-1527. doi: 10.1002/jcph.754. Epub 2016 Jun 8.
8
Canakinumab for secondary prevention of atherosclerotic disease.卡那奴单抗用于动脉粥样硬化疾病的二级预防。
Expert Opin Biol Ther. 2018 Feb;18(2):215-220. doi: 10.1080/14712598.2018.1420776. Epub 2017 Dec 27.
9
One target-two different binding modes: structural insights into gevokizumab and canakinumab interactions to interleukin-1β.一个靶点两种不同结合模式：对 gevokizumab 和 canakinumab 与白细胞介素-1β相互作用的结构见解。
J Mol Biol. 2013 Jan 9;425(1):94-111. doi: 10.1016/j.jmb.2012.09.021. Epub 2012 Oct 3.
10
Fetal exposure to canakinumab: a report of three pregnancies.胎儿接触卡那单抗：三例妊娠报告。
Clin Rheumatol. 2022 Apr;41(4):1261-1263. doi: 10.1007/s10067-022-06060-y. Epub 2022 Jan 12.

引用本文的文献

1
Evolving tumor microenvironment: Driving cancer initiation and progression in cardiovascular diseases.不断演变的肿瘤微环境：推动心血管疾病中的癌症发生与进展
iScience. 2025 Aug 18;28(9):113387. doi: 10.1016/j.isci.2025.113387. eCollection 2025 Sep 19.
2
The Role of Interleukin 1β in the Pathogenesis of Lung Cancer.白细胞介素1β在肺癌发病机制中的作用
JTO Clin Res Rep. 2020 Feb 11;1(1):100001. doi: 10.1016/j.jtocrr.2020.100001. eCollection 2020 Mar.
3
Intranasal Iloprost Prevents Tumors in a Murine Lung Carcinogenesis Model.经鼻给予伊洛前列素可预防小鼠肺癌发生模型中的肿瘤。
Cancer Prev Res (Phila). 2022 Jan;15(1):11-16. doi: 10.1158/1940-6207.CAPR-21-0086. Epub 2021 Sep 23.
4
Mendelian randomization study of interleukin (IL)-1 family and lung cancer.孟德尔随机化研究白细胞介素（IL）-1 家族与肺癌。
Sci Rep. 2021 Sep 2;11(1):17606. doi: 10.1038/s41598-021-97099-5.
5
2020 Innovation-Based Optimism for Lung Cancer Outcomes.2020 年肺癌治疗结果的创新乐观主义。
Oncologist. 2021 Mar;26(3):e454-e472. doi: 10.1002/onco.13590. Epub 2020 Dec 20.
6
Mechanistic Biomarkers Informative of Both Cancer and Cardiovascular Disease: JACC State-of-the-Art Review.具有癌症和心血管疾病双重指示意义的机制生物标志物：美国心脏病学会的最新综述。
J Am Coll Cardiol. 2020 Jun 2;75(21):2726-2737. doi: 10.1016/j.jacc.2020.03.067.
7
Organ System Crosstalk in Cardiometabolic Disease in the Age of Multimorbidity.多病共存时代心脏代谢疾病中的器官系统相互作用
Front Cardiovasc Med. 2020 Apr 28;7:64. doi: 10.3389/fcvm.2020.00064. eCollection 2020.
8
Recent advances in cardio-oncology: a report from the 'Heart Failure Association 2019 and World Congress on Acute Heart Failure 2019'.最近在心脏肿瘤学方面的进展：来自“心力衰竭协会 2019 年和急性心力衰竭世界大会 2019 年”的报告。
ESC Heart Fail. 2019 Dec;6(6):1140-1148. doi: 10.1002/ehf2.12551. Epub 2019 Dec 28.
9
Immunopathogenesis of Immune Checkpoint Inhibitor-Related Adverse Events: Roles of the Intestinal Microbiome and Th17 Cells.免疫检查点抑制剂相关不良事件的免疫发病机制：肠道微生物组和 Th17 细胞的作用。
Front Immunol. 2019 Sep 26;10:2254. doi: 10.3389/fimmu.2019.02254. eCollection 2019.
10
The emerging roles of inflammasome-dependent cytokines in cancer development.炎症小体依赖性细胞因子在癌症发展中的新兴作用。
EMBO Rep. 2019 Jun;20(6). doi: 10.15252/embr.201847575. Epub 2019 May 17.

本文引用的文献

1
Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial.卡那单抗抑制白细胞介素-1β对动脉粥样硬化患者肺癌发病的影响：一项随机、双盲、安慰剂对照试验的探索性结果。
Lancet. 2017 Oct 21;390(10105):1833-1842. doi: 10.1016/S0140-6736(17)32247-X. Epub 2017 Aug 27.
2
Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease.卡那奴单抗治疗动脉粥样硬化疾病的抗炎疗法。
N Engl J Med. 2017 Sep 21;377(12):1119-1131. doi: 10.1056/NEJMoa1707914. Epub 2017 Aug 27.
3
Siltuximab for multicentric Castleman's disease: a randomised, double-blind, placebo-controlled trial.西妥昔单抗治疗多发性 Castleman 病的随机、双盲、安慰剂对照试验。
Lancet Oncol. 2014 Aug;15(9):966-74. doi: 10.1016/S1470-2045(14)70319-5. Epub 2014 Jul 17.
4
Phase 2 randomized study of bortezomib-melphalan-prednisone with or without siltuximab (anti-IL-6) in multiple myeloma.硼替佐米-美法仑-泼尼松联合或不联合西妥昔单抗（抗白细胞介素-6）治疗多发性骨髓瘤的2期随机研究。
Blood. 2014 Jun 26;123(26):4136-42. doi: 10.1182/blood-2013-12-546374. Epub 2014 May 15.
5
IL-1 is required for tumor invasiveness and angiogenesis.白细胞介素-1是肿瘤侵袭和血管生成所必需的。
Proc Natl Acad Sci U S A. 2003 Mar 4;100(5):2645-50. doi: 10.1073/pnas.0437939100. Epub 2003 Feb 21.

卡那单抗与肺癌：耐人寻味，但确有其事？

Canakinumab and Lung Cancer: Intriguing, but Is It Real?

机构信息

Massachusetts General Hospital Cancer Center, Boston, Massachusetts, USA

Massachusetts General Hospital Cancer Center, Boston, Massachusetts, USA.

出版信息

Oncologist. 2018 Jun;23(6):637-638. doi: 10.1634/theoncologist.2018-0116. Epub 2018 Apr 17.

DOI:10.1634/theoncologist.2018-0116
PMID:29666299
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6067938/
Abstract

The relationship between inflammation and cancer is complicated. This editorial calls attention to intriguing findings of the CANTOS trial, which was designed to test the hypothesis that an anti‐inflammatory intervention could reduce the incidence of heart attacks, stroke, or cardiovascular death in patients with elevated C‐reactive protein.

摘要

炎症与癌症之间的关系很复杂。这篇社论提请人们注意 CANTOS 试验的有趣发现，该试验旨在检验假设，即抗炎干预是否可以降低 C 反应蛋白升高的患者心脏病发作、中风或心血管死亡的发生率。